Publications by authors named "O K Acar"
Highly selective inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6is) have emerged as a standart of care for first- and second-line therapies in combination with endocrine therapy (ET) for HR+/HER2- metastatic breast cancer (MBC) patients. It has been reported that combination therapy is more effective than ET alone and is safe in elderly patients as well as young patients. Nevertheless, elderly and very old patients with HR+/HER2-MBC treated with CDK4/6 inhibitor (CDK4/6i) combinations are relatively underrepresented in randomized controlled trials.
View Article and Find Full Text PDFEvaluation of atherogenic indices in patients with endometrioma: A case-control study.
Taiwan J Obstet Gynecol
November 2024
Objective: To evaluate the cardiovascular risk status of patients with endometriosis using serum lipid parameters and atherogenic indices.
Materials And Methods: The study was retrospective, single-centric, case-control study, involving a total of 190 women, including 95 cases and 95 control groups. Blood parameters, inflammatory markers as serum pan-immune-inflammation value, systemic immune-inflammation index, systemical inflammation-response index, and the atherogenic indices as Atherogenic Index of Plasma (AIP), Castelli Risk Index I and II (CRI-I and II), and the Atherogenic Coefficient (AC) were calculated.
Objective: The pivotal prognostic determinant for recurrence and survival in surgically treated gastric cancer (GC) patients remains the lymph node status. Despite the adoption of D2 lymph node dissection as the standard approach in recent years, its association with increased morbidity in elderly patients raises concerns. This study aims to explore the prognostic significance of the Positive Lymph Node Ratio (PLNR) score in the context of recurrence and survival among elderly patients with surgically treated GC.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the role of Her2 status in early stage triple negative breast cancer (TNBC) patients undergoing neoadjuvant chemotherapy, revealing conflicting results regarding its prognostic impact.
- A total of 620 female TNBC patients were analyzed, with 68.9% having Her2-0 and 31.1% having Her2-low status; the rates of pathological complete response (pCR) were similar between these groups.
- While the Her2-0 group showed better disease-free survival (DFS), the overall survival (OS) rates were similar between the two groups, indicating the need for further research into the implications of Her2 status in this treatment context.